///Human MIP-3 alpha (CCL20) Recombinant

Human MIP-3 alpha (CCL20) Recombinant

Category:

$70.00$2,700.00

SKU: RKP78556 Tags: , , , , , , , , ,

Description

Accession
P78556
Source
Optimized DNA sequence encoding Human MIP-3 alpha (CCL20) mature chain was expressed in Escherichia Coli.
Molecular weight
Human CCL20, generated by the proteolytic removal of the signal peptide and propeptide and has a calculated molecular mass of approximately8 kDa. RecombinantCCL-20 is a monomeric protein consisting of amino acid residue subunits and migrates as an approximately8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE.
Purity
>98%, as determined by SDS-PAGE and HPLC
Biological Activity
Determined by its ability to chemoattract human monocytes using a concentration range of.0-40.0 ng/ml.

Protein Sequence
MCCTKSLLLA ALMSVLLLHL CGESEAASNF DCCLGYTDRI LHPKFIVGFT RQLANEGCDI NAIIFHTKKK LSVCANPKQT WVKYIVRLLS KKVKNM
Endotoxin
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation
Recombinant CCL20 was lyophilized from a.2 μm filteredmM PB,100mM NaCl solution pH.5.
Reconstitution
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage
The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Interactor
P51684
Biological Process
Biological Process
Molecular function
Molecular function

Methods

Expression of CCR6/CCL20 in NSCLC tissue samples.

  • PCR signal for CCL20, CCR6 and beta-actin in three NSCLC tumor samples .

Langerin-positive cells and CCL20 expression are reduced in lesional skin of EV patients.

  • Sections of normal human skin and lesional skin from EV patients were stained using antibodies against langerin or CCL20 and hematoxylin.

Langerin-positive cells and CCL20 expression are reduced in lesional skin of EV patients.

  • Sections of normal human skin and lesional skin from EV patients were stained using antibodies against langerin or CCL20 and hematoxylin.
Stay in the loop
For new product information and regular updates on our product range please fill your details
Loading